Occasional Diagnosis of Synchronous Renal Cell Carcinoma during Staging of Other Primary Tumors

Synchronous renal cell cancer (RCC) associated with primary neoplasms of other organs or tissues represents a rare diagnostic report during life. Recently, the widespread use of new diagnostic techniques (echography, computed tomography and magnetic resonance imaging) has permitted diagnosis of clinically silent RCC. We report 6 RCC cases occasionally diagnosed during initial staging of a primary cancer of other organs: 1 rhinopharyngeal carcinoma, 1 gastric cancer, 1 Waldenstrom's disease, 1 non-Hodgkin's lymphoma, 2 breast cancer. RCC was clinically silent in all patients. The diagnostic problems related to a report of a renal mass in patients with neoplastic disease at other sites and the consequent therapeutic implications are discussed.

Download Full-text

Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report

Case Reports in Oncology ◽

10.1159/000513743 ◽

2021 ◽

pp. 269-273

Author(s):

Charles Marchand Crety ◽

Estelle Vigneau ◽

Camille Invernizzi

Keyword(s):

Renal Cell Cancer ◽

Renal Cell ◽

Stereotactic Body Radiation Therapy ◽

Clinical Presentation ◽

Histopathological Examination ◽

Cell Cancer ◽

Papillary Renal Cell Carcinoma ◽

Complete Response ◽

Resonance Imaging ◽

The Right

Nasosinus metastases from kidney cancer are an unusual clinical presentation although some cases are reported in the literature. Among these cases, sphenoidal metastases are even rarer. Here we report a case of lone sphenoid metastasis in patients with papillary renal cell cancer. Eight months after radical nephrectomy, the patient presented with progressively worsening diplopia. Magnetic resonance imaging showed a mass in the right sphenoid sinus. Histopathological examination of the biopsy sample confirmed diagnosis of sinonasal metastasis from papillary renal cell carcinoma. The patient was declined for surgical management and received stereotactic body radiation therapy. Reassessment MRI at 4 months showed a complete response of the treated sphenoid lesion.

Download Full-text

Unusual endophytic non-enhancing tumour in the renal pelvis: a diagnostic dilemma

BMJ Case Reports ◽

10.1136/bcr-2021-245037 ◽

2021 ◽

Vol 14 (9) ◽

pp. e245037

Author(s):

Murali Krishna ◽

Santosh Kumar ◽

Kalpesh Mahesh Parmar ◽

Venkatesh Dhana Sekaran

Keyword(s):

Renal Cell ◽

Cell Cancer ◽

Diagnostic Techniques ◽

Molecular Diagnostic ◽

Molecular Diagnostic Techniques ◽

Imaging Features ◽

Diagnostic Dilemma ◽

Upper Tract Urothelial Cancer ◽

Cell Variant ◽

Clear Cell Variant

Renal cell cancer (RCC) is incidentally detected on imaging in 50%–60% of cases. Among the RCCs, clear cell variant is most common and classically seen as heterogenous enhancing lesion on CT imaging. Hypoenhancing mass presents a diagnostic dilemma with differential diagnosis being urothelial carcinoma, fat poor angiomyolipoma, oncocytoma or rarer variants of RCC. Such cases require further evaluation in form of urine cytology or newer molecular diagnostic techniques. Here, we present a case of renal mass with minimal enhancement on CT scan and imaging features suggestive of upper tract urothelial cancer. Final histopathology revealed the mass to be chromophobe variant of renal cell carcinoma.

Download Full-text

The Timing of Immunotherapy and Nephrectomy in Multimodality Treatment of Metastatic Renal Cell Carcinoma

Technology in Cancer Research & Treatment ◽

10.1177/153303460300200304 ◽

2003 ◽

Vol 2 (3) ◽

pp. 205-210 ◽

Cited By ~ 6

Author(s):

Axel Bex ◽

Simon Horenblas ◽

Gijsbert C. de Gast

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Cell Cancer ◽

Multimodality Treatment ◽

Interferon Alfa ◽

Prolonged Survival ◽

Treatment Modalities ◽

Primary Tumors

Multimodality treatment of metastatic renal cell carcinoma with immunotherapy and cytoreductive surgery is controversial. Especially the benefit of removing asymptomatic primary tumors in synchronous metastatic renal cell cancer has been debated since several non-randomized, retrospective studies revealed an improved response to immunotherapy and prolonged survival following initial nephrectomy. Two recent randomized prospective trials both demonstrated a prolonged survival in those who were randomly assigned to undergo nephrectomy of the primary tumor prior to treatment with interferon alfa-2b than in those who were assigned to undergo treatment with interferon alfa-2b alone. In these trials the survival benefit was limited and strongly influenced by overall performance score. The timing of immunotherapy, either as neoadjuvant (prior to nephrectomy) or adjuvant treatment (following nephrectomy) in the multimodality approach of synchronous metastatic renal cell carcinoma remains controversial. Selection of patients, the possible mechanisms underlying the survival advantage of the combination of nephrectomy and immunotherapy, and the timing of the treatment modalities are discussed herein.

Download Full-text

P14.03 Shifting trends and entity-specific aspects in patients with brain metastasis: real-life analysis from 6031 individuals over an observation period of 30 years

Neuro-Oncology ◽

10.1093/neuonc/noab180.132 ◽

2021 ◽

Vol 23 (Supplement_2) ◽

pp. ii38-ii38

Author(s):

A Steindl ◽

T J Brunner ◽

K Heimbach ◽

K Schweighart ◽

G M Moser ◽

...

Keyword(s):

Breast Cancer ◽

Lung Cancer ◽

Brain Metastasis ◽

Primary Tumor ◽

Renal Cell ◽

Cell Cancer ◽

Real Life ◽

Neurosurgical Procedures ◽

Primary Tumors ◽

Observation Period

Abstract BACKGROUND We aimed to investigate the changing clinical characteristics of patients with brain metastases (BM) over the last three decades as the foundation for modern BM specific clinical trial planning. MATERIAL AND METHODS 6031 patients with newly diagnosed BM from different solid tumors treated between 1986–2020 were identified from the Vienna Brain Metastasis Registry. RESULTS The fraction of BM originating from the most common BM causing primary tumors (lung cancer, breast cancer and melanoma) was stable over the observation period from 1986–2020. BM from renal cell carcinoma, colorectal cancer and cancer of unknown primary (CUP) decreased over time (p<0.001). Synchronous diagnosis of BM and primary tumor was more frequently observed in lung cancer and CUP patients compared to breast cancer patients (p<0.001). An increasing fraction of patients presented with asymptomatic BM (1986–1999: 20.2% vs. 2010–2020: 30.4%; p<0.001), specifically in lung cancer (p<0.001), melanoma (p<0.001) and renal cell cancer (p=0.004). A decrease of neurosurgical procedures (1986–1999: 39.3% vs. 2010–2020: 20.4%) and an increase of radiation treatments (1986–1999: 56.5% vs. 2010–2020: 73.0%) and systemic therapies (1986–1999: 0.6% vs. 2010–2020: 2.4%; p<0.001) was observed. Furthermore, median overall survival significantly increased across entities (1986–1999: 5 months vs. 2010–2020: 7 months; p=0.001). Intracranial progression as the cause of death increased across entities (p< 0.001). The prognostic DS-GPA (Hazard ratio [HR] 1.42; p< 0.001) and the Lung-molGPA (HR 1.67; p<0.001) could be validated. CONCLUSION We observed changes of BM presentation and clinical parameters during the observation period depending on primary tumor origins. Future BM studies should follow an entity-specific approach and address the characteristics of modern BM cohorts.

Download Full-text

Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications

Therapeutic Advances in Medical Oncology ◽

10.1177/1758834016687261 ◽

2017 ◽

Vol 9 (4) ◽

pp. 287-298 ◽

Cited By ~ 2

Author(s):

Che-Kai Tsao ◽

Bobby Liaw ◽

Catherine He ◽

Matthew D. Galsky ◽

John Sfakianos ◽

...

Keyword(s):

Growth Factor ◽

Renal Cell Cancer ◽

Renal Cell ◽

Kinase Inhibitors ◽

Cell Cancer ◽

Growth Factor Receptor ◽

Treatment Resistance ◽

Therapeutic Implications ◽

Resistance Patterns ◽

The Usa

Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC.

Download Full-text

Magnetic Resonance Imaging of Renal Cell Cancer

Renal Cell Cancer ◽

10.1007/978-1-84628-763-3_9 ◽

2008 ◽

pp. 101-126

Author(s):

Els L.F. Nijs ◽

Raymond H. Oyen

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Resonance Imaging

Download Full-text

Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer

Urology ◽

10.1016/j.urology.2007.11.096 ◽

2008 ◽

Vol 71 (4) ◽

pp. 708-712 ◽

Cited By ~ 52

Author(s):

Alexander R. Guimaraes ◽

Shahin Tabatabei ◽

Douglas Dahl ◽

W. Scott McDougal ◽

Ralph Weissleder ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Pilot Study ◽

Magnetic Resonance ◽

Lymph Nodes ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Resonance Imaging

Download Full-text

Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in HLRCC

10.1101/296194 ◽

2018 ◽

Cited By ~ 1

Author(s):

Yang Xu ◽

Paul Taylor ◽

Joshua Andrade ◽

Beatrix Ueberheide ◽

Brian Shuch ◽

...

Keyword(s):

Renal Cell ◽

Germ Line ◽

Tyrosine Phosphatase ◽

Cell Cancer ◽

Fumarate Hydratase ◽

High Sensitivity ◽

Papillary Renal Cell Carcinoma ◽

Neoplastic Disease ◽

Cancer Syndrome ◽

Inherited Cancer

AbstractHereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an inherited cancer syndrome associated with a highly aggressive form of type 2 papillary renal cell carcinoma (PRCC). Germ line inactivating alterations in Fumarate Hydratase (FH) cause HLRCC, and result in elevated levels of reactive oxygen species (ROS). Recent work indicates that FH -/-PRCC cells have increased ABL1 activation, which promotes tumor growth, but how ABL1 is activated remained unclear. Oxidation can regulate protein-tyrosine phosphatase (PTP) catalytic activity; conceivably, ROS-catalyzed inactivation of an ABL-directed PTP might account for ABL1 activation in this malignancy. Previously, our group developed “q-oxPTPome,” a method that can globally monitor the oxidation of classical PTPs. We have now refined the q-oxPTPome approach, increasing its sensitivity by >10X. Applying q-oxPTPome to FH-deficient cell models shows that multiple PTPs are either highly oxidized (including PTPN12) or overexpressed. In general, highly oxidized PTPs were those that have relatively high sensitivity to exogenous H2O2. Most PTP oxidation in FH-deficient cells is reversible, although nearly 40% of PTPN13 is oxidized irreversibly to the sulfonic acid state. Using “substrate-trapping mutants”, we mapped PTPs to their putative substrates, and found that only PTPN12 could target ABL1. Furthermore, knockdown experiments identify PTPN12 as the major ABL1 phosphatase in HLRCC. Overall, our results show that ROS-induced PTPN12 oxidation accounts for ABL1 phosphorylation in HLRCC-associated PRCC, reveal a novel mechanism for inactivating a tumor suppressor gene product, and establish a direct link between pathological PTP oxidation and neoplastic disease.

Download Full-text